GlassScriptPhysician profile
Philip Charles Devore
NPI 1366409062
$20,640.10
in general payments reported to CMS, 2019-2025
61 companies · $3,597 in 2025
The $3,597 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,947 · 2020: $2,683 · 2021: $3,427 · 2022: $2,804 · 2023: $2,700 · 2024: $2,483 · 2025: $3,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,779.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,333.51 | 2019-2025 | |
| Abbvie INC. | $1,595.18 | 2019-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $1,564.66 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,498.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,412.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,149.81 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,149.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $1,104.75 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,069.32 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Exact Sciences Corporation | $653.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $501.85 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $407.51 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $382.58 | 2019-2025 | Trintellix, Entyvio |
| Astellas Pharma US INC | $347.53 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $323.78 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Devore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.